Regulus Therapeutics Inc represents values of scientific innovation, collaboration, and commitment to improving patients' lives. The company's corporate philosophy revolves around developing breakthrough RNA-based therapeutics to address unmet medical needs. Regulus Therapeutics is focused on leveraging its deep expertise in microRNA and oligonucleotide-based therapeutics to develop innovative treatment options for diseases with limited or no available treatment options. Through its cutting-edge research and dedication to advancing the field of RNA therapeutics, Regulus Therapeutics aims to make a meaningful impact in the lives of patients and create value for its stakeholders.

Regulus Therapeutics Inc primarily operates in the United States, focusing on the development of innovative medicines. With headquarters in California and operations located in San Diego, the company is deeply rooted in the biopharmaceutical industry in the U.S. Regulus Therapeutics Inc primarily operates in the domestic market, continuously working towards advancements in the field of medicine.

Regulus Therapeutics Inc has achieved significant milestones in its journey. The company successfully advanced its promising pipeline, focusing on discovering and developing innovative RNA-targeted therapeutics. Notably, Regulus Therapeutics has advanced multiple programs into clinical development, including RG-101, an investigational therapy for Hepatitis C Virus. In addition, the company has formed strategic collaborations with renowned partners to further strengthen its research and development efforts. Regulus Therapeutics Inc has consistently shown dedication and commitment towards revolutionizing healthcare through RNA-based therapeutics, becoming a leading player in the field.

Regulus Therapeutics Inc. is a biopharmaceutical company that focuses on the discovery, development, and commercialization of innovative medicines. Founded in 2007, Regulus Therapeutics specializes in the research and development of microRNA therapeutics, which play a crucial role in regulating gene expression. The company has a strong expertise in developing drugs for various diseases, including cancer, fibrosis, and metabolic disorders. Regulus Therapeutics has formed strategic collaborations with major pharmaceutical companies to advance their pipeline and accelerate drug development. With a commitment to improving patient lives, Regulus Therapeutics continues to drive scientific advancements and deliver potential therapeutic solutions.

The main competitors of Regulus Therapeutics Inc in the market include companies like Alnylam Pharmaceuticals and Ionis Pharmaceuticals. These companies operate in the field of RNA-targeted therapeutics, similar to Regulus Therapeutics Inc. Competition exists within the industry as these companies strive to develop innovative and effective RNA-based therapies for various diseases.

Regulus Therapeutics Inc is primarily active in the biotechnology industry.

The business model of Regulus Therapeutics Inc revolves around developing and commercializing innovative medicines based on microRNA technology. Regulus focuses on discovering and developing drugs targeting microRNAs involved in regulating key disease pathways. By leveraging its expertise in this emerging field, the company aims to address unmet medical needs across various therapeutic areas, including fibrosis, immune-inflammatory diseases, and metabolic disorders. Regulus is committed to advancing its pipeline of potential therapeutics and collaborating with partners to deliver novel treatments to patients.

Az Regulus Therapeutics P/E mutatója -0,71.

Az Regulus Therapeutics KUV 0.

Az AlleAktien Minőségi Score Regulus Therapeutics esetében 4/10.

A Regulus Therapeutics esetében jelenleg nem számítható ki az árbevétel.

A(z) várt Regulus Therapeutics nyereség -40,74 Mió. USD.

Regulus Therapeutics Inc. is a biotechnology company focused on the development of therapies for chronic diseases. The company was founded in 2007 in San Diego, California. Regulus Therapeutics Inc. is a subsidiary of Alnylam Pharmaceuticals and Ionis Pharmaceuticals. The business model of Regulus Therapeutics is based on the identification of miRNAs that play a role in the development of diseases and the development of therapies that modulate these miRNAs. The company specializes in chronic diseases of the nervous system, liver, and circulatory system. The company is divided into three divisions: research and development, marketing and sales, and operations. The research department develops therapy options for specific diseases using a proprietary technology platform that allows for the targeted development of drugs against individual miRNAs. An important product of Regulus Therapeutics Inc. is the miR-122 inhibitor RG-101. This is a therapy option for patients with chronic hepatitis C infection (HCV). The product has proven to be effective in clinical trials and is already being marketed in some countries. Additionally, the company is working on developing products for other diseases. Regulus Therapeutics has entered into a licensing agreement with Sanofi to develop therapies for autoimmune diseases and cancer. The marketing and sales department of Regulus Therapeutics Inc. is responsible for selling products to hospitals, doctors, and pharmacies. There is close collaboration with clinicians and scientists to align the products with the needs of patients. The operations department of Regulus Therapeutics Inc. is responsible for the administrative and financial aspects of the company. It ensures that the different departments work together and achieve the company's goals. In summary, the business model of Regulus Therapeutics Inc. is based on the development of therapies for diseases of the nervous system, liver, and circulatory system. miRNAs are modulated specifically to develop drugs that are effective against individual diseases. Regulus Therapeutics works closely with clinicians and scientists in the field of research and development to tailor the products to the needs of patients. The company has already made a name for itself in some countries with the miR-122 inhibitor RG-101 and is actively working on developing products for other diseases.

A(z) Regulus Therapeutics évente alkalommal oszt ki 0 USD összegű osztalékot.

A Regulus Therapeutics esetében jelenleg nem lehet kiszámítani a osztalékot, vagy a vállalat nem fizet osztalékot.

A(z) Regulus Therapeutics ISIN kódja: US75915K2006.

A Regulus Therapeutics WKN-je A2JB9V.

Az Regulus Therapeutics tőzsdei rövidítése RGLS.

Az elmúlt 12 hónapban a(z) Regulus Therapeutics osztalékot fizetett összegben. Ez körülbelül osztalékhozamnak felel meg. A következő 12 hóban a(z) Regulus Therapeutics várhatóan 0 USD összegű osztalékot fog fizetni.

A(z) Regulus Therapeutics jelenlegi osztalékhozama .

A(z) Regulus Therapeutics negyedévente fizet osztalékot. Az osztalékokat a következő hónapokban osztják ki: .

A Regulus Therapeutics az elmúlt 0 évben minden évben fizetett osztalékot.

A következő 12 hónapban 0 USD összegű osztalékra számítanak. Ez 0 % osztalékhozamnak felel meg.

A(z) Regulus Therapeutics a(z) 'Egészség' szektorhoz van besorolva.

Az utolsó, Regulus Therapeutics által 2024. 08. 07.-án/én fizetett 0 USD összegű osztalék megszerzéséhez a részvénynek az ex-nap előtti 2024. 08. 07.-nál kellett lennie a portfóliódban.

Az utolsó osztalék kifizetése 2024. 08. 07. időpontban történt.

2023 évben a Regulus Therapeutics 0 USD összegű osztalékot fizetett ki.

Az Regulus Therapeutics osztalékait USD fizeti ki.